Dawson James analyst Jason Kolbert maintained a Buy rating on Cytosorbents (CTSO – Research Report) on August 3 and set a price target of $16.00. The company’s shares closed last Friday at $2.10.
Kolbert covers the Healthcare sector, focusing on stocks such as Sorrento Therapeutics, Can-Fite BioPharma, and Citius Pharmaceuticals. According to TipRanks, Kolbert has an average return of -0.9% and a 36.50% success rate on recommended stocks.
Currently, the analyst consensus on Cytosorbents is a Moderate Buy with an average price target of $12.50, representing a 495.24% upside. In a report released on August 3, H.C. Wainwright also maintained a Buy rating on the stock with a $9.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $9.80 and a one-year low of $1.69. Currently, Cytosorbents has an average volume of 263.3K.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CTSO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
Read More on CTSO:
- Dawson James Sticks to Its Hold Rating for Caladrius Biosciences (CLBS)
- Dawson James Sticks to Their Buy Rating for Profire Energy (PFIE)
- Vuzix (VUZI) Gets a Buy from Dawson James
- Goldman Sachs Keeps Their Hold Rating on Weave Communications (WEAV)
- Jefferies Reaffirms Their Hold Rating on Sharp (SHCAY)
